NRx Pharmaceuticals (NASDAQ:NRXP) Shares Break Above Fifty Day Moving Average - Here's What Happened

NRx Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • NRx Pharmaceuticals shares rose 14.3% and moved above their 50-day moving average of $2.76, trading as high as $2.91 before last changing hands at $2.80.
  • The company reported FDA approval of preservative-free ketamine and said its commercial launch is underway, with an initial order received; shipments are expected to begin by January 2027.
  • NRx’s operating loss widened to $8.1 million from $4.0 million, while it ended September with $19.8 million in cash and no convertible debt. The company reported a smaller-than-expected quarterly loss, but revenue missed estimates.
  • Interested in NRx Pharmaceuticals? Here are five stocks we like better.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) shares passed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $2.76 and traded as high as $2.91. NRx Pharmaceuticals shares last traded at $2.80, with a volume of 2,108,875 shares changing hands.

Key Stories Impacting NRx Pharmaceuticals

Investors following NRXP have been watching these stories:

  • Positive Sentiment: NRx reported FDA approval of preservative-free ketamine and said its commercial launch is underway, with a 17-person sales force and an initial order received. The company estimates a roughly $400 million U.S. market growing about 15% annually; shipments are expected to begin by January 2027. NRx Q3 results and corporate update
  • Neutral Sentiment: NRx says it is targeting a rolling NRX-100 NDA submission by year-end and expects to begin testing its new subcutaneous ketamine product, NRX-200, in 2027. These are prospective milestones, not yet achieved. Ketamine market and NRX-100 plans
  • Negative Sentiment: Operating loss widened to $8.1 million from $4.0 million, largely as selling and administrative costs increased ahead of the launch. NRx ended September with $19.8 million in cash and no convertible debt, but continued commercialization and development will require effective execution and cash management. NRx Q3 financial results

Analyst Ratings Changes

NRXP has been the subject of several recent analyst reports. BTIG Research upped their price target on NRx Pharmaceuticals from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Wednesday, November 11th. HC Wainwright restated a "buy" rating on shares of NRx Pharmaceuticals in a research note on Tuesday, August 25th. Wolfe Research initiated coverage on shares of NRx Pharmaceuticals in a report on Thursday, October 15th. They set an "outperform" rating on the stock. Wall Street Zen downgraded shares of NRx Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Finally, Zacks Research upgraded shares of NRx Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Monday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $35.00.

Get Our Latest Stock Report on NRXP

NRx Pharmaceuticals Trading Up 14.3%

The firm's 50 day moving average price is $2.76 and its two-hundred day moving average price is $2.97. The company has a market capitalization of $122.21 million, a price-to-earnings ratio of -8.24 and a beta of 2.11.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.16. The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.28 million. As a group, equities research analysts predict that NRx Pharmaceuticals, Inc. will post -1.14 EPS for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Large investors have recently bought and sold shares of the company. B Group Inc. boosted its stake in NRx Pharmaceuticals by 4.5% in the third quarter. B Group Inc. now owns 4,277,200 shares of the company's stock valued at $12,489,000 after buying an additional 185,433 shares in the last quarter. Marshall Wace LLP boosted its position in shares of NRx Pharmaceuticals by 411.4% during the 3rd quarter. Marshall Wace LLP now owns 995,172 shares of the company's stock valued at $2,906,000 after purchasing an additional 800,592 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in NRx Pharmaceuticals by 30.0% in the third quarter. Commonwealth Equity Services LLC now owns 590,768 shares of the company's stock worth $1,725,000 after purchasing an additional 136,350 shares during the period. Prime Capital Investment Advisors LLC acquired a new stake in NRx Pharmaceuticals in the third quarter valued at approximately $364,000. Finally, SBI Securities Co. Ltd. lifted its position in NRx Pharmaceuticals by 292.1% in the 3rd quarter. SBI Securities Co. Ltd. now owns 20,001 shares of the company's stock valued at $58,000 after acquiring an additional 14,900 shares in the last quarter. 4.27% of the stock is currently owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments. The company's candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in NRx Pharmaceuticals Right Now?

Before you consider NRx Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NRx Pharmaceuticals wasn't on the list.

While NRx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines